Evidence map›Paper›PMID 41366130›Full record

ArticleProstate cancer and prostatic diseases2026

Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.

Udit Singhal, Ralph Jiang, James A Proudfoot, Elizabeth Chase, Krithika Suresh, Elai Davicioni, Tudor Borza, Michael J Zelefsky, Brian J Davis, Brad J Stish and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Development and validation of a preoperativeEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Udit Singhal *Department of Urology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA. usinghal@med.umich.edu.ORCID http://orcid.org/0000-0002-3928-9476
Ralph Jiang *Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
James A ProudfootVeracyte Inc., San Francisco, California, 94080, USA.
Elizabeth ChaseDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, 48109, USA.
Krithika SureshDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
Elai DavicioniVeracyte Inc., San Francisco, California, 94080, USA.
Tudor BorzaDepartment of Urology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA.
Michael J ZelefskyDepartment of Radiation Oncology, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Brian J DavisDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Brad J StishDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, MN, 55905, USA.
Stephen J FreedlandDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.ORCID http://orcid.org/0000-0002-8104-6419
Martha K TerrisDepartment of Urology, Medical College of Georgia at Augusta, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0002-3843-7270
William J AronsonDepartment of Urology, University of California Los Angeles Medical Center, Los Angeles, CA, 90095, USA.
Matthew R CooperbergDepartment of Urology, University of California San Francisco Medical Center, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0003-4339-6685
Fabio Y MoraesDepartment of Oncology, Kingston General Hospital, Queen's University, Kingston, ON, Canada.ORCID http://orcid.org/0000-0003-3407-9215
Alejandro BerlinDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Curtiland DevilleDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0003-4846-6486
Nicholas G ZaorskyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
Soumyajit RoyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.ORCID http://orcid.org/0000-0001-6617-5522
Angela Y JiaDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.ORCID http://orcid.org/0000-0002-0812-2614
Jonathan E ShoagDepartment of Radiation Urology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
William C JacksonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.ORCID http://orcid.org/0000-0002-5973-4741
Matthew SchipperDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
Todd M MorganDepartment of Urology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID http://orcid.org/0000-0002-1140-0603
Robert T DessDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenomic classifiers are endorsed by guidelines and commonly used to inform prognosis in prostate cancer. We aimed to understand the distribution of genomic risk within the validated staging collaboration for cancer of the prostate (STAR-CAP) and propose a system integrating genomic and clinicopathologic risk. We hypothesized that genomic heterogeneity would have implications on risk estimates and may inform treatment decisions. MATERIALS AND

methodsGenomic risk was assessed using the Decipher genomic classifier in two separate multi-institutional, prospectively collected population-based registries: (1) Decipher Genomics Resource for Intelligent Discovery (GRID) [n = 50,891] and (2) Michigan Urological Surgery Improvement Collaborative (MUSIC-Decipher) [n = 1602]. The primary endpoint was estimated prostate cancer-specific mortality (PCSM), and secondary endpoint was distant metastasis (DM). Marginal risk estimates provided by STAR-CAP were combined with hazard ratios of Decipher to calculate integrated risk estimates.

resultsMedian age and PSA was 68 years and 6.2 ng/mL in GRID, and 66 years and 10.5 ng/mL in MUSIC. The GRID population had 50.2%, 18.5%, and 31.4% with low-, intermediate-, and high-Decipher risk, compared to 48.0%, 16.2%, and 35.8% in MUSIC. Decipher-based genomic risk varied across STAR-CAP stages in both registries. Estimates of 10-year PCSM (0.1% to 48.8%) and DM (0.3%-72.9%) varied widely after integration of clinical-genomic risk. Use of an integrated Decipher-STAR-CAP system led to significant stage reclassification, including 23.4% upstaging and 45.6% downstaging at least one stage.

conclusionsThese findings suggest integration of genomic and clinicopathologic risk may lead to more nuanced risk assessment in prostate cancer and may help individualize treatment consideration.

Indexed as

Biomarkers, TumorGenomicsProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm StagingPrognosisRegistriesRisk AssessmentRisk FactorsBiomarkers, Tumor

Identifiers

PMID41366130
PMCPMC13472942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.